Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gary Albert, Iksung Cho, +26

New England Journal of Medicine

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Vivek Shinde, Sutika Bhikha, Zaheer Hoosain, +46

New England Journal of Medicine

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M. Mallory, Neil Formica, Susan Pfeiffer, +39

The Lancet Infectious Diseases

VaccinationVaccine SafetyVaccine DevelopmentImmunologyVaccine Testing +5

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

Shabir A. Madhi, Dhayendre Moodley, Sherika Hanley, +44

The Lancet HIV

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses

Carolyn Rydyznski Moderbacher, Christina Kim, José Mateus, +8

Journal of Clinical Investigation

Adaptive Immune SystemImmunologyImmune RegulationImmunodominanceImmunologic Mechanism +17

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents

Germán Áñez, Lisa M. Dunkle, Cynthia L. Gay, +15

JAMA Network Open

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gregory M. Glenn, Gary Albert, +26

ImmunologyImmunodominanceImmunotherapeuticsCovid-19Cross-protection +18

Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

Vivek Shinde, Sutika Bhikha, Zaheer Hoosain, +46

ImmunologyPreliminary EfficacyCovid-19 EpidemiologyCovid-19Vaccine Surveillance +14

Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M–Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine

Vivek Shinde, Rongman Cai, Joyce S. Plested, +16

Clinical Infectious Diseases

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial

Raburn M. Mallory, Neil Formica, Susan Pfeiffer, +16

ImmunologyImmunodominanceCovid-19Vaccine TargetVaccine Surveillance +16